ArticleCancer discovery2021
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.
Open access · bronzeAbstract readComment
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers.
0numbers the graph read from it
0cells of the map it votes in
272citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
272 citing papers in PubMed, 393 citations in OpenAlex.
- Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Structural and Biophysical Characterization of Aminobenzo[ACS medicinal chemistry letters · 2026Article
- A dual assault on KRAS.Nature chemical biology · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Targeted therapeutic strategies forTranslational lung cancer research · 2026Review
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications · 2026Article
- New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.Cancer science · 2026Review
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences · 2026Review
- Serum SOS1 as a prognostic biomarker and therapeutic target for progressive liver disease.iScience · 2026Article
- Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy.BMC cancer · 2026Article
- Pancreatic Cancer: Translating Tumor Biology into Actionability.Cancer discovery · 2026Review
- Filgotinib induces apoptosis in colorectal cancer cells by activating the p53 signaling pathway.Molecular biology reports · 2026Article
- From paradox to target: IFN-β hijacks MEK signaling to drive a cell death-evading dormant phenotype in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Precision Targeting ofInternational journal of molecular sciences · 2026Review
- Inhibition of Pax6 sumoylation suppresses the tumorigenicity of pancreatic cancer cells.Cell death and differentiation · 2026Article
- RiboScreenBiomedicines · 2026Review
- CAF-derived PTGDS drives pancreatic cancer neuroendocrine differentiation and chemoresistance via PAQR9-MAPK.Oncogenesis · 2026Article
- Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma.NPJ precision oncology · 2026Article
212 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
33 authors at 3 institutions in 2 countries.
Marco H Hofmann *Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com norbert.kraut@boehringer-ingelheim.com.ORCID 0000-0001-7557-1156
Michael Gmachl *Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Juergen Ramharter *Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Fabio SavareseBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Daniel GerlachBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0001-9338-3765
Joseph R MarszalekTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael P SandersonBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Dirk KesslerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0001-6808-9011
Francesca TrapaniBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Heribert ArnhofBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Klaus RumpelBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Dana-Adriana BotesteanuBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Peter EttmayerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0002-8422-2625
Thomas GerstbergerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Christiane KofinkBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0003-2515-8843
Tobias WunbergBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0001-6521-8201
Andreas ZoephelBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Szu-Chin FuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jessica L TehTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1841-671X
Jark BöttcherBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0003-2189-5926
Nikolai PototschnigBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Franziska SchachingerBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0002-8830-2286
Katharina SchipanyBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Simone LiebBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Christopher P VellanoTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jonathan C O'ConnellForma Therapeutics, Watertown, Massachusetts.
Rachel L MendesForma Therapeutics, Watertown, Massachusetts.
Jurgen MollBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Mark PetronczkiBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0003-0139-5692
Timothy P HeffernanTRACTION Platform, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3166-8922
Mark PearsonBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Darryl B McConnellBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.ORCID 0000-0002-2537-3458
Norbert KrautBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com norbert.kraut@boehringer-ingelheim.com.ORCID 0000-0003-3941-7105
Boehringer Ingelheim (Austria) · ATThe University of Texas MD Anderson Cancer Center · USForma Therapeutics (United States) · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
PubMed holds no abstract for this paper.
Indexed as
Lung NeoplasmsProto-Oncogene Proteins p21(ras)Cell Line, TumorHumansMitogen-Activated Protein Kinase KinasesMutationNucleotidesProtein Kinase InhibitorsKRAS protein, humanMitogen-Activated Protein Kinase KinasesNucleotidesProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.